{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:36:49Z","timestamp":1792193809896,"version":"4.4.0"},"reference-count":125,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Persistent genital infection with high-risk human papilloma virus (hrHPV) causes the vast majority of cases of cervical cancer. Early screening, ongoing surveillance, and accurate diagnosis are crucial for the elimination of cervical cancer. New screening guidelines for testing in asymptomatic healthy populations and management guidelines for managing abnormal results have been published by professional organizations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Content<\/jats:title><jats:p>This guidance document addresses key questions related to cervical cancer screening and management including currently available cervical cancer screening tests and the testing strategies for cervical cancer screening. This guidance document introduces the most recently updated screening guidelines regarding age to start screening, age to stop screening, and frequencies of routine screening as well as risk-based management guidelines for screening and surveillance. This guidance document also summarizes the methodologies for the diagnosis of cervical cancer. Additionally, we propose a report template for human papilloma virus (HPV) and cervical cancer detection to facilitate interpretation of results and clinical decision-making.<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p>Currently available cervical cancer screening tests include hrHPV testing and cervical cytology screening. The screening strategies can be primary HPV screening, co-testing with HPV testing and cervical cytology, and cervical cytology alone. The new American Society for Colposcopy and Cervical Pathology guidelines recommend variable frequencies of screening and surveillance based on risk. To implement these guidelines, an ideal laboratory report should include the indication for the test (screening, surveillance, or diagnostic workup of symptomatic patients); type of test (primary HPV screening, co-testing, or cytology alone); clinical history of the patient; and prior as well as current testing results.<\/jats:p><\/jats:sec>","DOI":"10.1093\/jalm\/jfac142","type":"journal-article","created":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T20:19:48Z","timestamp":1678220388000},"page":"382-406","source":"Crossref","is-referenced-by-count":8,"title":["AACC Guidance Document on Cervical Cancer Detection: Screening, Surveillance, and Diagnosis"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0666-7127","authenticated-orcid":false,"given":"Yusheng","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Pennsylvania State University College of Medicine , Hershey, PA , USA"},{"name":"Department of Pharmacology, Pennsylvania State University College of Medicine , Hershey, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Feldman","sequence":"additional","affiliation":[{"name":"Departments of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuk On Annie","family":"Leung","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, McGill University Health Centre, McGill University , Montreal, QC , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H","family":"Creer","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Pennsylvania State University College of Medicine , Hershey, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Warrick","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Pennsylvania State University College of Medicine , Hershey, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Williams","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Pennsylvania State University College of Medicine , Hershey, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Mastorides","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine Service, James A. Haley Veterans\u2019 Hospital , Tampa, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,6]]},"reference":[{"key":"2023050412164705300_jfac142-B1","volume-title":"International agency for research on cancer, world health organization. WHO classification of tumours of female reproductive organs","author":"Kurman","year":"2014","edition":"4th Ed"},{"key":"2023050412164705300_jfac142-B2","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/jcp.55.4.244","article-title":"The causal relation between human papillomavirus and cervical cancer","volume":"55","author":"Bosch","year":"2002","journal-title":"J Clin Pathol"},{"key":"2023050412164705300_jfac142-B3","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/jnci\/djq562","article-title":"Human papillomavirus testing in the prevention of cervical cancer","volume":"103","author":"Schiffman","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"2023050412164705300_jfac142-B4","volume-title":"Blaustein's pathology of the female genital tract","author":"Kurman","year":"2013","edition":"6th Ed"},{"key":"2023050412164705300_jfac142-B5","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/cjp2.27","article-title":"Somatic mutation in PIK3CA is a late event in cervical carcinogenesis","volume":"1","author":"Verlaat","year":"2015","journal-title":"J Pathol Clin Res"},{"key":"2023050412164705300_jfac142-B6","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nature21386","article-title":"Integrated genomic and molecular characterization of cervical cancer","volume":"543","author":"Cancer Genome Atlas Research Network","year":"2017","journal-title":"Nature"},{"key":"2023050412164705300_jfac142-B7","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/LGT.0000000000000525","article-title":"2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors","volume":"24","author":"Perkins","year":"2020","journal-title":"J Low Genit Tract Dis"},{"key":"2023050412164705300_jfac142-B8","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2018.10400","article-title":"Screening for cervical cancer with high-risk human papillomavirus testing: updated evidence report and systematic review for the US Preventive Services Task Force","volume":"320","author":"Melnikow","year":"2018","journal-title":"JAMA"},{"key":"2023050412164705300_jfac142-B9","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/LGT.0000000000000529","article-title":"Risk estimates supporting the 2019 ASCCP risk-based management consensus guidelines","volume":"24","author":"Egemen","year":"2020","journal-title":"J Low Genit Tract Dis"},{"key":"2023050412164705300_jfac142-B10","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jcv.2013.12.001","article-title":"Clinical performance of RNA and DNA based HPV testing in a colposcopy setting: influence of assay target, cut off and age","volume":"59","author":"Cuschieri","year":"2014","journal-title":"J Clin Virol"},{"key":"2023050412164705300_jfac142-B11","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/cncy.21687","article-title":"Clinical performance of the Food and Drug Administration-approved high-risk HPV test for the detection of high-grade cervicovaginal lesions","volume":"124","author":"Zhou","year":"2016","journal-title":"Cancer Cytopathol"},{"key":"2023050412164705300_jfac142-B12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.cmi.2017.05.020","article-title":"Concordant testing results between various human papillomavirus assays in primary cervical cancer screening: systematic review","volume":"24","author":"de Thurah","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2023050412164705300_jfac142-B13","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/bjc.2013.22","article-title":"Comparing the performance of six human papillomavirus tests in a screening population","volume":"108","author":"Cuzick","year":"2013","journal-title":"Br J Cancer"},{"key":"2023050412164705300_jfac142-B14","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jasc.2019.06.001","article-title":"A review of the FDA-approved molecular testing platforms for human papillomavirus","volume":"8","author":"Salazar","year":"2019","journal-title":"J Am Soc Cytopathol"},{"key":"2023050412164705300_jfac142-B15","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/cncy.21875","article-title":"Performance of Aptima and Cobas HPV testing platforms in detecting high-grade cervical dysplasia and cancer","volume":"125","author":"Ge","year":"2017","journal-title":"Cancer Cytopathol"},{"key":"2023050412164705300_jfac142-B16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jcv.2014.11.017","article-title":"Comparison of the Roche Cobas\u00ae 4800 HPV assay to Digene Hybrid Capture 2, Roche Linear Array and Roche Amplicor for detection of high-risk human papillomavirus genotypes in women undergoing treatment for cervical dysplasia","volume":"62","author":"Phillips","year":"2015","journal-title":"J Clin Virol"},{"key":"2023050412164705300_jfac142-B17","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.ejca.2013.01.018","article-title":"Comparison of human papillomavirus testing strategies for triage of women referred with low-grade cytological abnormalities","volume":"49","author":"Mesher","year":"2013","journal-title":"Eur J Cancer"},{"key":"2023050412164705300_jfac142-B18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.pvr.2016.01.003","article-title":"Clinical and analytical performance of the BD Onclarity HPV assay for detection of CIN2 + lesions on SurePath samples","volume":"2","author":"Ejegod","year":"2016","journal-title":"Papillomavirus Res"},{"key":"2023050412164705300_jfac142-B19","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jcv.2016.06.015","article-title":"A comparison of different human papillomavirus tests in PreservCyt versus SurePath in a referral population\u2014PREDICTORS 4","volume":"82","author":"Cuzick","year":"2016","journal-title":"J Clin Virol"},{"key":"2023050412164705300_jfac142-B20","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/cncr.22285","article-title":"Human papillomavirus testing using Hybrid Capture II with SurePath collection: initial evaluation and longitudinal data provide clinical validation for this method","volume":"108","author":"Ko","year":"2006","journal-title":"Cancer"},{"key":"2023050412164705300_jfac142-B21","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ygyno.2010.04.013","article-title":"Clinical validation of the Cervista HPV HR and 16\/18 genotyping tests for use in women with ASC-US cytology","volume":"118","author":"Einstein","year":"2010","journal-title":"Gynecol Oncol"},{"key":"2023050412164705300_jfac142-B22","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/dc.23221","article-title":"Analytical performance of Cervista HPV 16\/18 in SurePath Pap specimens","volume":"43","author":"Guo","year":"2015","journal-title":"Diagn Cytopathol"},{"key":"2023050412164705300_jfac142-B23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3802\/jgo.2012.23.1.5","article-title":"Comparison of the Seeplex HPV4A ACE and the Cervista HPV assays for the detection of HPV in Hybrid Capture 2 positive media","volume":"23","author":"Min","year":"2012","journal-title":"J Gynecol Oncol"},{"key":"2023050412164705300_jfac142-B24","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1365-2303.2011.00923.x","article-title":"Comparison of the clinical performance of an HPV mRNA test and an HPV DNA test in triage of atypical squamous cells of undetermined significance (ASC-US)","volume":"23","author":"Waldstrom","year":"2012","journal-title":"Cytopathology"},{"key":"2023050412164705300_jfac142-B25","doi-asserted-by":"crossref","first-page":"817","DOI":"10.5858\/1999-123-0817-POAFBT","article-title":"Performance of a fluid-based, thin-layer papanicolaou smear method in the clinical setting of an independent laboratory and an outpatient screening population in New England","volume":"123","author":"D\u00edaz-Rosario","year":"1999","journal-title":"Arch Pathol Lab Med"},{"key":"2023050412164705300_jfac142-B26","doi-asserted-by":"crossref","first-page":"200","DOI":"10.5858\/2003-127-200-CAOCPT","article-title":"Comparative analysis of conventional papanicolaou tests and a fluid-based thin-layer method","volume":"127","author":"Limaye","year":"2003","journal-title":"Arch Pathol Lab Med"},{"key":"2023050412164705300_jfac142-B27","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/dc.22842","article-title":"Gynecologic cytology on conventional and liquid-based preparations: a comprehensive review of similarities and differences","volume":"41","author":"Hoda","year":"2013","journal-title":"Diagn Cytopathol"},{"key":"2023050412164705300_jfac142-B28","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/00128360-200410000-00009","article-title":"Multicenter direct to vial evaluation of a liquid-based Pap test","volume":"8","author":"Hatch","year":"2004","journal-title":"J Low Genit Tract Dis"},{"key":"2023050412164705300_jfac142-B29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/cncr.23257","article-title":"Effectiveness of the Thin Prep imaging system in the detection of adenocarcinoma of the gynecologic system","volume":"114","author":"Friedlander","year":"2008","journal-title":"Cancer"},{"key":"2023050412164705300_jfac142-B30","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/dc.21046","article-title":"Accuracy of ThinPrep imaging system in detecting atypical glandular cells","volume":"37","author":"Jayamohan","year":"2009","journal-title":"Diagn Cytopathol"},{"key":"2023050412164705300_jfac142-B31","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/dc.10358","article-title":"Focalpoint slide classification algorithms show robust performance in classification of high-grade lesions on SurePath liquid-based cervical cytology slides","volume":"30","author":"Parker","year":"2004","journal-title":"Diagn Cytopathol"},{"key":"2023050412164705300_jfac142-B32","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/dc.23931","article-title":"Automated screening of papanicolaou tests: a review of the literature","volume":"47","author":"Thrall","year":"2019","journal-title":"Diagn Cytopathol"},{"key":"2023050412164705300_jfac142-B33","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000381842","article-title":"The Pap test and Bethesda 2014","volume":"59","author":"Nayar","year":"2015","journal-title":"Acta Cytol"},{"key":"2023050412164705300_jfac142-B34","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJM199802123380703","article-title":"Natural history of cervicovaginal papillomavirus infection in young women","volume":"338","author":"Ho","year":"1998","journal-title":"N Engl J Med"},{"key":"2023050412164705300_jfac142-B35","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/LGT.0000000000000528","article-title":"2019 ASCCP risk-based management consensus guidelines: methods for risk estimation, recommended management, and validation","volume":"24","author":"Cheung","year":"2020","journal-title":"J Low Genit Tract Dis"},{"key":"2023050412164705300_jfac142-B36","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/ijc.29026","article-title":"Comparative performance of novel self-sampling methods in detecting high-risk human papillomavirus in 30 130 women not attending cervical screening","volume":"136","author":"Bosgraaf","year":"2015","journal-title":"Int J Cancer"},{"key":"2023050412164705300_jfac142-B37","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jcv.2016.06.016","article-title":"Direct comparison of two vaginal self-sampling devices for the detection of human papillomavirus infections","volume":"82","author":"Jentschke","year":"2016","journal-title":"J Clin Virol"},{"key":"2023050412164705300_jfac142-B38","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1128\/JCM.01506-12","article-title":"Dry storage and transport of a cervicovaginal self-sample by use of the Evalyn brush, providing reliable human papillomavirus detection combined with comfort for women","volume":"50","author":"van Baars","year":"2012","journal-title":"J Clin Microbiol"},{"key":"2023050412164705300_jfac142-B39","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.pvr.2018.04.005","article-title":"Time and temperature dependent analytical stability of dry-collected Evalyn HPV self-sampling brush for cervical cancer screening","volume":"5","author":"Ejegod","year":"2018","journal-title":"Papillomavirus Res"},{"key":"2023050412164705300_jfac142-B40","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S1470-2045(18)30763-0","article-title":"Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, paired screen-positive, non-inferiority trial","volume":"20","author":"Polman","year":"2019","journal-title":"Lancet Oncol"},{"key":"2023050412164705300_jfac142-B41","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1016\/S0140-6736(11)61522-5","article-title":"Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial","volume":"378","author":"Lazcano-Ponce","year":"2011","journal-title":"Lancet"},{"key":"2023050412164705300_jfac142-B42","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ypmed.2017.05.021","article-title":"High-risk human papillomavirus detection in self-sampling compared to physician-taken smear in a responder population of the Dutch cervical screening: results of the VERA study","volume":"101","author":"Ketelaars","year":"2017","journal-title":"Prev Med"},{"key":"2023050412164705300_jfac142-B43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-018-3254-y","article-title":"Good concordance of HPV detection between cervico-vaginal self-samples and general practitioner-collected samples using the cobas 4800 HPV DNA test","volume":"18","author":"Tranberg","year":"2018","journal-title":"BMC Infect Dis"},{"key":"2023050412164705300_jfac142-B44","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S1470-2045(13)70570-9","article-title":"Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis","volume":"15","author":"Arbyn","year":"2014","journal-title":"Lancet Oncol"},{"key":"2023050412164705300_jfac142-B45","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/ijgo.12538","article-title":"Comparison between professional sampling and self-sampling for HPV-based cervical cancer screening among postmenopausal women","volume":"142","author":"Bergengren","year":"2018","journal-title":"Int J Gynaecol Obstet"},{"key":"2023050412164705300_jfac142-B46","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.3390\/cancers12041053","article-title":"Self-collection for cervical screening programs: from research to reality","volume":"12","author":"Hawkes","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2023050412164705300_jfac142-B47","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1186\/s12889-021-11554-6","article-title":"Self-collection for HPV-based cervical screening: a qualitative evidence meta-synthesis","volume":"21","author":"Camara","year":"2021","journal-title":"BMC Public Health"},{"key":"2023050412164705300_jfac142-B48","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2019.105953","article-title":"Cost-effectiveness studies of HPV self-sampling: a systematic review","volume":"132","author":"Malone","year":"2020","journal-title":"Prev Med"},{"key":"2023050412164705300_jfac142-B49","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/2046-4053-2-35","article-title":"Screening for cervical cancer: a systematic review and meta-analysis","volume":"2","author":"Peirson","year":"2013","journal-title":"Syst Rev"},{"key":"2023050412164705300_jfac142-B50","doi-asserted-by":"crossref","first-page":"687","DOI":"10.7326\/0003-4819-155-10-201111150-00376","article-title":"Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. Preventive Services Task Force","volume":"155","author":"Whitlock","year":"2011","journal-title":"Ann Intern Med"},{"key":"2023050412164705300_jfac142-B51","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1056\/NEJMoa0808516","article-title":"HPV screening for cervical cancer in rural India","volume":"360","author":"Sankaranarayanan","year":"2009","journal-title":"N Engl J Med"},{"key":"2023050412164705300_jfac142-B52","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1001\/jama.2018.10897","article-title":"Screening for cervical cancer: US Preventive Services Task Force recommendation statement","volume":"320","author":"Curry","year":"2018","journal-title":"JAMA"},{"key":"2023050412164705300_jfac142-B53","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3322\/caac.21628","article-title":"Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society","volume":"70","author":"Fontham","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"2023050412164705300_jfac142-B54","author":"US Food and Drug Administration. FDA executive summary: new approaches in the evaluation for high-risk human papillomavirus nucleic acid detection devices. Prepared for the March 8, 2019, meeting of the Microbiology Devices Panel of the Medical Devices Advisory Committee"},{"key":"2023050412164705300_jfac142-B55","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ygyno.2014.11.076","article-title":"Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test","volume":"136","author":"Wright","year":"2015","journal-title":"Gynecol Oncol"},{"key":"2023050412164705300_jfac142-B56","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/jama.297.8.813","article-title":"Prevalence of HPV infection among females in the United States","volume":"297","author":"Dunne","year":"2007","journal-title":"JAMA"},{"key":"2023050412164705300_jfac142-B57","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1086\/320696","article-title":"Determinants of genital human papillomavirus detection in a US population","volume":"183","author":"Peyton","year":"2001","journal-title":"J Infect Dis"},{"key":"2023050412164705300_jfac142-B58","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ygyno.2014.12.022","article-title":"Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance","volume":"136","author":"Huh","year":"2015","journal-title":"Gynecol Oncol"},{"key":"2023050412164705300_jfac142-B59","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S0140-6736(13)62218-7","article-title":"Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials","volume":"383","author":"Ronco","year":"2014","journal-title":"Lancet"},{"key":"2023050412164705300_jfac142-B60","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJMoa073204","article-title":"Human papillomavirus and papanicolaou tests to screen for cervical cancer","volume":"357","author":"Naucler","year":"2007","journal-title":"New Engl J Med"},{"key":"2023050412164705300_jfac142-B61","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/S0140-6736(07)61450-0","article-title":"Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial","volume":"370","author":"Bulkmans","year":"2007","journal-title":"Lancet"},{"key":"2023050412164705300_jfac142-B62","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1470-2045(09)70360-2","article-title":"Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial","volume":"11","author":"Ronco","year":"2010","journal-title":"Lancet Oncol"},{"key":"2023050412164705300_jfac142-B63","doi-asserted-by":"crossref","first-page":"a1754","DOI":"10.1136\/bmj.a1754","article-title":"Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study","volume":"337","author":"Dillner","year":"2008","journal-title":"BMJ (Clinical research ed)"},{"key":"2023050412164705300_jfac142-B64","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(11)70145-0","article-title":"Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice","volume":"12","author":"Katki","year":"2011","journal-title":"Lancet Oncol"},{"key":"2023050412164705300_jfac142-B65","doi-asserted-by":"crossref","first-page":"c1804","DOI":"10.1136\/bmj.c1804","article-title":"Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme","volume":"340","author":"Anttila","year":"2010","journal-title":"BMJ (Clinical research ed)"},{"key":"2023050412164705300_jfac142-B66","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1158\/1055-9965.EPI-05-0231","article-title":"Incidence trends of adenocarcinoma of the cervix in 13 European countries","volume":"14","author":"Bray","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2023050412164705300_jfac142-B67","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00006250-200305000-00043","article-title":"Screening interval and risk of invasive squamous cell cervical cancer","volume":"101","author":"Miller","year":"2003","journal-title":"Obstet Gynecol"},{"key":"2023050412164705300_jfac142-B68","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/00006250-200012000-00032","article-title":"Frequency of cervical smear abnormalities within 3 years of normal cytology","volume":"96","author":"Sawaya","year":"2000","journal-title":"Obstet Gynecol"},{"key":"2023050412164705300_jfac142-B69","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1001\/jama.2017.19872","article-title":"Screening for cervical cancer in primary care: a decision analysis for the US Preventive Services Task Force","volume":"320","author":"Kim","year":"2018","journal-title":"JAMA"},{"key":"2023050412164705300_jfac142-B70","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1056\/NEJMoa035419","article-title":"Risk of cervical cancer associated with extending the interval between cervical-cancer screenings","volume":"349","author":"Sawaya","year":"2003","journal-title":"N Engl J Med"},{"key":"2023050412164705300_jfac142-B71","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S1470-2045(06)70731-8","article-title":"Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial","volume":"7","author":"Ronco","year":"2006","journal-title":"Lancet Oncol"},{"key":"2023050412164705300_jfac142-B72","doi-asserted-by":"crossref","first-page":"e7789","DOI":"10.1136\/bmj.e7789","article-title":"Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland","volume":"345","author":"Leinonen","year":"2012","journal-title":"BMJ"},{"key":"2023050412164705300_jfac142-B73","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jama.2018.7464","article-title":"Effect of screening with primary cervical HPV testing vs cytology testing on high-grade cervical intraepithelial neoplasia at 48 months: the HPV FOCAL randomized clinical trial","volume":"320","author":"Ogilvie","year":"2018","journal-title":"JAMA"},{"key":"2023050412164705300_jfac142-B74","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(09)70156-1","article-title":"HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial","volume":"10","author":"Kitchener","year":"2009","journal-title":"Lancet Oncol"},{"key":"2023050412164705300_jfac142-B75","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/jnci\/95.1.46","article-title":"Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis","volume":"95","author":"Sherman","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"2023050412164705300_jfac142-B76","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1093\/jnci\/djq356","article-title":"Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence","volume":"102","author":"Kjaer","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"2023050412164705300_jfac142-B77","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/01.AOG.0000109426.82624.f8","article-title":"Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening","volume":"103","author":"Wright TC","year":"2004","journal-title":"Obstet Gynecol"},{"key":"2023050412164705300_jfac142-B78","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/jnci\/dji187","article-title":"The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice","volume":"97","author":"Khan","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"2023050412164705300_jfac142-B79","doi-asserted-by":"crossref","first-page":"880","DOI":"10.7326\/0003-4819-156-12-201206190-00424","article-title":"Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement","volume":"156","author":"Moyer","year":"2012","journal-title":"Ann Intern Med"},{"key":"2023050412164705300_jfac142-B80","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1001\/archinte.168.17.1881","article-title":"Trade-offs in cervical cancer prevention: balancing benefits and risks","volume":"168","author":"Stout","year":"2008","journal-title":"Arch Intern Med"},{"key":"2023050412164705300_jfac142-B81","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/ajcp\/aqaa074","article-title":"Contributions of liquid-based (papanicolaou) cytology and human papillomavirus testing in cotesting for detection of cervical cancer and precancer in the United States","volume":"154","author":"Kaufman","year":"2020","journal-title":"Am J Clin Pathol"},{"key":"2023050412164705300_jfac142-B82","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1097\/AOG.0b013e31826e4609","article-title":"Cervical carcinoma rates among young females in the United States","volume":"120","author":"Benard","year":"2012","journal-title":"Obstet Gynecol"},{"key":"2023050412164705300_jfac142-B83","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ajog.2004.01.043","article-title":"Diagnoses and outcomes in cervical cancer screening: a population-based study","volume":"191","author":"Insinga","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"2023050412164705300_jfac142-B84","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/sj.bjc.6602049","article-title":"Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort","volume":"91","author":"Peto","year":"2004","journal-title":"Br J Cancer"},{"key":"2023050412164705300_jfac142-B85","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.1172\/JCI57149","article-title":"The known unknowns of HPV natural history","volume":"121","author":"Gravitt","year":"2011","journal-title":"J Clin Invest"},{"key":"2023050412164705300_jfac142-B86","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/CEJ.0000000000000360","article-title":"Cervical cancer screening and subsequent procedures in women under the age of 25 years between 2007 and 2013 in France: a nationwide French healthcare database study","volume":"27","author":"Maura","year":"2018","journal-title":"Eur J Cancer Prev"},{"key":"2023050412164705300_jfac142-B87","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1038\/bjc.2014.65","article-title":"Benefits and harms of cervical screening from age 20 years compared with screening from age 25 years","volume":"110","author":"Landy","year":"2014","journal-title":"Br J Cancer"},{"key":"2023050412164705300_jfac142-B88","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/bjc.2013.322","article-title":"Characteristics and screening history of women diagnosed with cervical cancer aged 20\u201329 years","volume":"109","author":"Castanon","year":"2013","journal-title":"Br J Cancer"},{"key":"2023050412164705300_jfac142-B89","doi-asserted-by":"crossref","first-page":"718","DOI":"10.15585\/mmwr.mm6833a2","article-title":"National, regional, state, and selected local area vaccination coverage among adolescents aged 13\u201317 years\u2014United States, 2018","volume":"68","author":"Walker","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2023050412164705300_jfac142-B90","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ypmed.2018.07.005","article-title":"How confident can we be in the current guidelines for exiting cervical screening?","volume":"114","author":"Gravitt","year":"2018","journal-title":"Prev Med"},{"key":"2023050412164705300_jfac142-B91","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/LGT.0000000000000435","article-title":"Cervical cancer incidence among elderly women in Massachusetts compared with younger women","volume":"22","author":"Feldman","year":"2018","journal-title":"J Low Genit Tract Dis"},{"key":"2023050412164705300_jfac142-B92","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0140-6736(90)90552-G","article-title":"Screening for cancer of the cervix in elderly women","volume":"335","author":"Fletcher","year":"1990","journal-title":"Lancet"},{"key":"2023050412164705300_jfac142-B93","doi-asserted-by":"crossref","first-page":"520","DOI":"10.7326\/0003-4819-117-6-520","article-title":"Cost effectiveness of cervical cancer screening for the elderly","volume":"117","author":"Fahs","year":"1992","journal-title":"Ann Intern Med"},{"key":"2023050412164705300_jfac142-B94","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3109\/07357909309024834","article-title":"Pap smears, elderly women, and Medicare","volume":"11","author":"Power","year":"1993","journal-title":"Cancer Invest"},{"key":"2023050412164705300_jfac142-B95","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/LGT.0000000000000468","article-title":"Guidelines for cervical cancer screening in immunosuppressed women without HIV infection","volume":"23","author":"Moscicki","year":"2019","journal-title":"J Low Genit Tract Dis"},{"key":"2023050412164705300_jfac142-B96","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1097\/AOG.0000000000001713","article-title":"Committee Opinion No.675: management of vulvar intraepithelial neoplasia","volume":"128","author":"American College of Obstetrics and Gynecology","year":"2016","journal-title":"Obstet Gynecol"},{"key":"2023050412164705300_jfac142-B97","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ygyno.2017.10.029","article-title":"Vulvar intraepithelial neoplasia: risk factors for recurrence","volume":"148","author":"Satmary","year":"2018","journal-title":"Gynecol Oncol"},{"key":"2023050412164705300_jfac142-B98","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.bpobgyn.2014.07.010","article-title":"Vulvar intraepithelial neoplasia","volume":"28","author":"Preti","year":"2014","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"2023050412164705300_jfac142-B99","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ygyno.2015.11.023","article-title":"A common clinical dilemma: management of abnormal vaginal cytology and human papillomavirus test results","volume":"141","author":"Khan","year":"2016","journal-title":"Gynecol Oncol"},{"key":"2023050412164705300_jfac142-B100"},{"key":"2023050412164705300_jfac142-B101","doi-asserted-by":"crossref","first-page":"61S","DOI":"10.1097\/01.AOG.0000559030.66553.23","article-title":"Concurrent cervical and vulvar dysplasia and\/or cancer\u2014high likelihood in the immunocompromised [38E]","volume":"133","author":"Meinhardt","year":"2019","journal-title":"Obstet Gynecol"},{"key":"2023050412164705300_jfac142-B102","doi-asserted-by":"crossref","first-page":"46.e1","DOI":"10.1016\/j.ajog.2011.07.024","article-title":"The ATHENA human papillomavirus study: design, methods, and baseline results","volume":"206","author":"Wright","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"2023050412164705300_jfac142-B103","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ygyno.2018.04.007","article-title":"The Onclarity human papillomavirus trial: design, methods, and baseline results","volume":"149","author":"Stoler","year":"2018","journal-title":"Gynecol Oncol"},{"key":"2023050412164705300_jfac142-B104","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1309\/AJCPSD3ZXJXP7NNB","article-title":"Cervical histopathology variability among laboratories: a population-based statewide investigation","volume":"139","author":"Gage","year":"2013","journal-title":"Am J Clin Pathol"},{"key":"2023050412164705300_jfac142-B105","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/ijc.27608","article-title":"A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination","volume":"132","author":"Wheeler","year":"2013","journal-title":"Int J Cancer"},{"key":"2023050412164705300_jfac142-B106","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.amepre.2014.05.016","article-title":"Impact of the national breast and cervical cancer early detection program on cervical cancer mortality among uninsured low-income women in the U.S., 1991\u20132007","volume":"47","author":"Ekwueme","year":"2014","journal-title":"Am J Prev Med"},{"key":"2023050412164705300_jfac142-B107","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1136\/bmj.39363.471806.BE","article-title":"Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: population based cohort study","volume":"335","author":"Strander","year":"2007","journal-title":"BMJ"},{"issue":"Suppl 5","key":"2023050412164705300_jfac142-B108","doi-asserted-by":"crossref","first-page":"F88","DOI":"10.1016\/j.vaccine.2012.06.095","article-title":"Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer","volume":"30","author":"Arbyn","year":"2012","journal-title":"Vaccine"},{"key":"2023050412164705300_jfac142-B109","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/LGT.0000000000000526","article-title":"A systematic review of tests for postcolposcopy and posttreatment surveillance","volume":"24","author":"Clarke","year":"2020","journal-title":"J Low Genit Tract Dis"},{"key":"2023050412164705300_jfac142-B110","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/LGT.0000000000000322","article-title":"Evidence-based consensus recommendations for colposcopy practice for cervical cancer prevention in the United States","volume":"21","author":"Wentzensen","year":"2017","journal-title":"J Low Genit Tract Dis"},{"key":"2023050412164705300_jfac142-B111","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/LGT.0000000000000334","article-title":"ASCCP colposcopy standards: risk-based colposcopy practice","volume":"21","author":"Wentzensen","year":"2017","journal-title":"J Low Genit Tract Dis"},{"key":"2023050412164705300_jfac142-B112","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/LGT.0000000000000342","article-title":"ASCCP colposcopy standards: colposcopy quality improvement recommendations for the United States","volume":"21","author":"Mayeaux EJ","year":"2017","journal-title":"J Low Genit Tract Dis"},{"key":"2023050412164705300_jfac142-B113","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/LGT.0000000000000344","article-title":"Systematic review of international colposcopy quality improvement guidelines","volume":"21","author":"Mayeaux","year":"2017","journal-title":"J Low Genit Tract Dis"},{"key":"2023050412164705300_jfac142-B114","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1200\/JCO.2014.55.9948","article-title":"Multiple biopsies and detection of cervical cancer precursors at colposcopy","volume":"33","author":"Wentzensen","year":"2015","journal-title":"J Clin Oncol"},{"key":"2023050412164705300_jfac142-B115","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/1471-0528.13530","article-title":"Evidence supporting see-and-treat management of cervical intraepithelial neoplasia: a systematic review and meta-analysis","volume":"123","author":"Ebisch","year":"2016","journal-title":"BJOG"},{"issue":"Suppl 1","key":"2023050412164705300_jfac142-B116","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/LGT.0b013e318287d329","article-title":"2012 Updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors","volume":"17","author":"Massad","year":"2013","journal-title":"J Low Genit Tract Dis"},{"key":"2023050412164705300_jfac142-B117","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/pgp.0b013e31805152ab","article-title":"CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples","volume":"26","author":"Carreon","year":"2007","journal-title":"Int J Gynecol Pathol"},{"key":"2023050412164705300_jfac142-B118","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1038\/modpathol.2016.141","article-title":"P16ink4 and cytokeratin 7 immunostaining in predicting HSIL outcome for low-grade squamous intraepithelial lesions: a case series, literature review and commentary","volume":"29","author":"Huang","year":"2016","journal-title":"Mod Pathol"},{"key":"2023050412164705300_jfac142-B119","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1001\/jama.285.11.1500","article-title":"Atypical squamous cells of undetermined significance-low-grade squamous intraepithelial lesion triage study G. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage study","volume":"285","author":"Stoler","year":"2001","journal-title":"JAMA"},{"key":"2023050412164705300_jfac142-B120","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1097\/00000478-200211000-00001","article-title":"p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia","volume":"26","author":"Klaes","year":"2002","journal-title":"Am J Surg Pathol"},{"key":"2023050412164705300_jfac142-B121","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.5858\/arpa.LGT200570","article-title":"The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology","volume":"136","author":"Darragh","year":"2012","journal-title":"Arch Pathol Lab Med"},{"key":"2023050412164705300_jfac142-B122","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1001\/jamaoncol.2018.4270","article-title":"Five-year risk of cervical precancer following p16\/Ki-67 dual-stain triage of HPV-positive women","volume":"5","author":"Clarke","year":"2019","journal-title":"JAMA Oncol"},{"key":"2023050412164705300_jfac142-B123","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12905-017-0448-1","article-title":"Self-collected vaginal sampling for the detection of genital human papillomavirus (HPV) using CareHPV among Ghanaian women","volume":"17","author":"Obiri-Yeboah","year":"2017","journal-title":"BMC Womens Health"},{"key":"2023050412164705300_jfac142-B124","doi-asserted-by":"crossref","first-page":"e16970","DOI":"10.1097\/MD.0000000000016970","article-title":"HPV testing on vaginal\/cervical nurse-assisted self-samples versus clinician-taken specimens and the HPV prevalence, in Adama Town, Ethiopia","volume":"98","author":"Haile","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"2023050412164705300_jfac142-B125","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1186\/s12913-020-05214-5","article-title":"Uptake and acceptability of human papillomavirus self-sampling in rural and remote aboriginal communities: evaluation of a nurse-led community engagement model","volume":"20","author":"Dutton","year":"2020","journal-title":"BMC Health Serv Res"}],"container-title":["The Journal of Applied Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jalm\/article-pdf\/8\/2\/382\/50194637\/jfac142.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jalm\/article-pdf\/8\/2\/382\/50194637\/jfac142.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,3]],"date-time":"2023-12-03T09:55:38Z","timestamp":1701597338000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jalm\/article\/8\/2\/382\/7030135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,1]]},"references-count":125,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,3,6]]},"published-print":{"date-parts":[[2023,3,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jalm\/jfac142","relation":{},"ISSN":["2475-7241"],"issn-type":[{"value":"2475-7241","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3,1]]},"published":{"date-parts":[[2023,3,1]]}}}